The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis

We evaluated the risk of worsening according to the length of exposure to interferon beta (IFNβ)ina large cohort of 2090 multiple sclerosis patients collected by the Italian MS Database Network. Overall 44-140 patient-visits with a follow-up of 22-143 patient-years were evaluated. Forty-one per cent of patients were exposed to IFNβ for up to 2 years, 39% for 2- 4 years and 20% for more than 4 years. A Cox regression model was used to analyse two clinical outcomes: disability progression and worsening of relapse rate. The technique of propensity score was applied to reduce bias in the comparison of non-randomized groups. The risks of disability progression (HR=0.23; 95% CI: 0.17 - 0.30) and worsening of relapse rate (HR=0.19; 95% CI: 0.14 - 0.27) were reduced by about 4- 5- fold in patients exposed to IFNβ for more than four years, compared with patients exposed for up to two years. The propensity score technique confirmed the findings. The proportion of days covered by IFNβ treatment was lower (P<0.0001) in patients exposed to IFNβ for up to two years than in other groups. A clinical stabilization over two years of IFNβ exposure may predict a subsequent good clinical response to treatment.

[1]  R. D'Agostino Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.

[2]  P. Bramanti,et al.  Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study. , 2004, Journal of evaluation in clinical practice.

[3]  V. Martinelli,et al.  A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients , 2003, Journal of neurology, neurosurgery, and psychiatry.

[4]  M. Trojano,et al.  Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy , 2003, Multiple sclerosis.

[5]  S. Vukusic,et al.  Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.

[6]  C. Granger,et al.  Multiple sclerosis characteristics in A frican A merican patients in the New York State Multiple Sclerosis C onsortium , 2003, Multiple sclerosis.

[7]  L. Munari,et al.  Interferons in relapsing remitting multiple sclerosis : a systematic review , 2022 .

[8]  Maria Liguori,et al.  Age‐related disability in multiple sclerosis , 2002, Annals of neurology.

[9]  M. Lauer,et al.  Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. , 2001, JAMA.

[10]  E. Celius,et al.  Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25‐year period , 2001, European journal of neurology.

[11]  S. Rasmussen,et al.  The Danish Multiple Sclerosis Registry. History, data collection and validity. , 2001, Danish medical bulletin.

[12]  L. Wallentin,et al.  Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.

[13]  A. Hartz,et al.  A comparison of observational studies and randomized, controlled trials , 2000, American journal of ophthalmology.

[14]  J. Concato,et al.  Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.

[15]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. , 1999, Brain : a journal of neurology.

[16]  T. Vollmer,et al.  The NARCOMS Patient Registry: A Resource for Investigators , 1999 .

[17]  B. Weinshenker,et al.  Databases in MS research: pitfalls and promises , 1999, Multiple sclerosis.

[18]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[19]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[20]  R. P. Kinkel,et al.  Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis , 1997, Neurology.

[21]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[22]  T. Pincus,et al.  What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols? , 1995, The Journal of rheumatology.

[23]  F. Wolfe,et al.  Data collection in the clinic. , 1995, Rheumatic diseases clinics of North America.

[24]  G. Serio,et al.  Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[25]  J. E. Rees,et al.  A prevalence survey of multiple sclerosis in Sussex. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[26]  N. Wood,et al.  Multiple sclerosis in the Cambridge health district of east Anglia. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[27]  C Confavreux,et al.  EDMUS, a European database for multiple sclerosis. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[28]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.

[29]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[30]  P H Plotz,et al.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. , 1986, The New England journal of medicine.

[31]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[32]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[33]  R. Califf,et al.  Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). , 1999, Circulation.

[34]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[35]  D. Paty,et al.  MS COSTAR: A computerized patient record adapted for clinical research purposes , 1994, Annals of neurology.